Why Reposition Compounds?
• Successfully repositioned drugs enter the market 3-5 years faster than a conventionally developed drug and as a consequence generate income sooner • Success rates for repurposed drugs are higher and costs are lower than de novo R&D • It is estimated that over 2,000 failed drugs are sitting on companies shelves and that this number grows at the rate of 150-200 drugs per year • The science to evaluate new diseases continues to evolve so that science led repurposing (rather than random screening) is a viable business model • Repositioning is expected to generate up to $20 billion in annual sales in 2012
Why paRtneR With thomson ReuteRs?
• Our unparallel access to chemical and biological data make us the best partner to assist your repurposing efforts The Thomson Reuters Cortellis™ Professional Services team includes highly experienced drug hunters and experts in biology, chemistry, translational medicine, and portfolio analysis. Working with you, our team will deliver a customized, multi-disciplined approach to drug repositioning for your organization. Employing our proprietary content in harmony with your in-house data, we will evaluate opportunities using three main methods to help you reposition compounds:
• 
